BioCryst Pharmaceuticals (BCRX) said Wednesday that Portuguese regulator Infarmed had recommended Orladeyo oral therapy to prevent recurrent hereditary angioedema attacks in patients 12 years old and older.
The company said Orladeyo, or berotralstat, is now licensed in 44 countries. The European Commission granted marketing authorization for Orladeyo in April 2021, the company added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。